FBIO
Fortress Biotech, Inc.
NasdaqCMUSDEQUITY
DELAYED
Last price
2.87
▲ 0.10 (3.61%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
2.80
Prev close
2.77
Day high
2.88
Day low
2.79
Volume
202.62K
Market cap
—
P/E (TTM)
—
52W range
2.18 – 4.53
Trailing performance
Returnvs SPY
1W
-2.05%
-0.7%
1M
-16.33%
-20.1%
3M
+3.24%
+0.1%
6M
-14.58%
-25.6%
YTD
-21.58%
-33.9%
1Y
+40.00%
+20.0%
3Y
-58.41%
-132.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on FBIO open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $63.26M | $57.67M | $84.51M | $75.74M | +9.7% |
| Operating revenue | $61.24M | $56.67M | $64.99M | $73.07M | +8.1% |
| Cost of revenue | $20.92M | $20.88M | $22.89M | $30.77M | +0.2% |
| Gross profit | $42.34M | $36.80M | $61.62M | $44.97M | +15.1% |
| Research & development | $11.90M | $56.88M | $106.07M | $134.88M | -79.1% |
| Selling, general & admin | $96.40M | $87.73M | $90.98M | $113.66M | +9.9% |
| Total operating expense | $112.56M | $148.04M | $200.82M | $248.53M | -24.0% |
| Operating income | -$70.22M | -$111.24M | -$139.20M | -$203.56M | +36.9% |
| Net interest income | -$7.62M | -$10.84M | -$12.31M | -$12.24M | +29.7% |
| Pre-tax income | -$33.53M | -$120.54M | -$153.63M | -$213.46M | +72.2% |
| Tax provision | -$620.00K | $312.00K | $521.00K | $449.00K | -298.7% |
| Net income | $6.82M | -$46.00M | -$60.64M | -$86.58M | +114.8% |
| Net income to common | -$1.88M | -$55.89M | -$68.67M | -$94.61M | +96.6% |
| Basic EPS | -0.07 | -2.69 | -8.47 | -14.55 | +97.4% |
| Diluted EPS | -0.07 | -2.69 | -8.47 | -14.55 | +97.4% |
| EBIT | -$24.83M | -$108.95M | -$141.72M | -$203.05M | +77.2% |
| EBITDA | -$20.16M | -$104.49M | -$135.72M | -$193.69M | +80.7% |
| Basic shares | 27.90M | 20.78M | 8.11M | 5.92M | +34.2% |
| Diluted shares | 27.90M | 20.78M | 8.11M | 5.92M | +34.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $79.38M | $57.26M | $80.93M | $178.27M | — | +38.6% |
| Cash & short-term investments | $79.38M | $57.26M | $80.93M | $178.27M | — | +38.6% |
| Accounts receivable | $29.78M | $10.23M | $15.22M | $28.21M | — | +191.1% |
| Inventory | $9.62M | $14.43M | $10.21M | $14.16M | — | -33.3% |
| Total current assets | $123.84M | $90.37M | $117.02M | $230.43M | — | +37.0% |
| Property, plant & equipment | $14.82M | $17.12M | $23.50M | $33.01M | — | -13.4% |
| Goodwill & intangibles | $27.61M | $31.86M | $20.29M | $27.20M | — | -13.4% |
| Total assets | $185.55M | $144.22M | $167.53M | $294.30M | — | +28.7% |
| Total current liabilities | $49.74M | $71.40M | $84.91M | $127.72M | — | -30.3% |
| Current debt | — | $625.00K | $3.00M | $10.18M | $5.32M | — |
| Long-term debt | $59.50M | $57.96M | $60.86M | $93.14M | — | +2.7% |
| Total debt | $74.30M | $75.96M | $84.66M | $127.34M | — | -2.2% |
| Total liabilities | $123.36M | $145.87M | $165.94M | $244.28M | — | -15.4% |
| Retained earnings | -$734.05M | -$740.87M | -$694.87M | -$634.23M | — | +0.9% |
| Shareholder equity | $49.87M | $22.74M | $22.54M | $41.72M | — | +119.3% |
| Working capital | $74.10M | $18.97M | $32.11M | $102.72M | — | +290.6% |
| Net tangible assets | $22.27M | -$9.13M | $2.26M | $14.52M | — | +344.0% |
| Shares issued | 31.36M | 27.91M | 15.09M | 7.37M | — | +12.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$32.91M | -$120.86M | -$154.15M | -$213.91M | — | +72.8% |
| Depreciation & amortisation | $4.66M | $4.46M | $6.00M | $9.35M | — | +4.4% |
| Stock-based compensation | $28.74M | $32.62M | $17.03M | $22.99M | — | -11.9% |
| Change in working capital | -$25.10M | -$8.13M | -$12.52M | -$715.00K | — | -208.8% |
| Operating cash flow | -$65.78M | -$80.19M | -$128.22M | -$179.40M | — | +18.0% |
| Capital expenditure | — | -$15.00M | -$8.10M | -$3.06M | -$16.35M | — |
| Investing cash flow | $10.12M | -$15.00M | -$2.10M | -$22.93M | — | +167.5% |
| Share buybacks | -$265.00K | $0 | -$400.00K | -$1.20M | — | — |
| Dividends paid | -$664.00K | -$4.71M | -$8.77M | -$8.78M | — | +85.9% |
| Financing cash flow | $77.44M | $70.64M | $32.74M | $75.32M | — | +9.6% |
| Free cash flow | -$65.78M | -$95.19M | -$136.32M | -$182.46M | — | +30.9% |
| End cash position | $80.60M | $58.81M | $83.36M | $180.95M | — | +37.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $16.04M | $16.08M | $17.63M | $16.41M | $13.14M | — | -0.3% |
| Operating revenue | $15.92M | $16.07M | $17.02M | $15.01M | $13.14M | — | -0.9% |
| Cost of revenue | $6.22M | $5.44M | $5.75M | $4.94M | $4.79M | — | +14.3% |
| Gross profit | $9.82M | $10.64M | $11.88M | $11.47M | $8.35M | — | -7.7% |
| Research & development | $540.00K | -$367.00K | $208.00K | $8.13M | $3.94M | — | +247.1% |
| Selling, general & admin | $15.89M | $14.73M | $17.41M | $38.76M | $25.66M | — | +7.9% |
| Total operating expense | $17.56M | $15.43M | $18.69M | $47.95M | $30.67M | — | +13.8% |
| Operating income | -$7.74M | -$4.79M | -$6.81M | -$36.47M | -$22.32M | — | -61.6% |
| Net interest income | -$2.80M | -$1.40M | -$2.01M | -$1.90M | -$2.31M | — | -99.3% |
| Pre-tax income | $142.29M | -$6.21M | $8.85M | -$11.65M | -$24.69M | — | +2,390.3% |
| Tax provision | $5.13M | -$816.00K | $26.00K | — | $0 | $336.00K | +728.9% |
| Net income | $110.37M | -$3.94M | $5.85M | $15.49M | -$10.58M | — | +2,903.5% |
| Net income to common | $108.36M | -$6.20M | $3.67M | $13.36M | -$12.71M | — | +1,848.4% |
| Basic EPS | 3.44 | — | 0.13 | 0.50 | -0.48 | — | — |
| Diluted EPS | 2.82 | — | 0.11 | 0.45 | -0.48 | — | — |
| EBIT | $144.06M | -$4.50M | $11.27M | -$9.58M | -$22.18M | — | +3,298.5% |
| EBITDA | $145.28M | -$3.35M | $12.43M | -$8.42M | -$20.99M | — | +4,440.6% |
| Basic shares | 31.54M | — | 27.24M | 26.88M | 26.45M | — | — |
| Diluted shares | 38.41M | — | 33.10M | 29.82M | 26.45M | — | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $255.84M | $79.38M | $86.22M | $74.39M | $91.34M | — | +222.3% |
| Cash & short-term investments | $255.84M | $79.38M | $86.22M | $74.39M | $91.34M | — | +222.3% |
| Accounts receivable | $24.99M | $29.78M | $17.98M | $15.64M | $18.02M | — | -16.1% |
| Inventory | $9.29M | $9.62M | $11.82M | $12.85M | $12.50M | — | -3.4% |
| Total current assets | $295.48M | $123.84M | $118.50M | $110.40M | $126.90M | — | +138.6% |
| Property, plant & equipment | $14.25M | $14.82M | $14.93M | $15.52M | $16.10M | — | -3.9% |
| Goodwill & intangibles | $26.48M | $27.61M | $28.67M | $29.73M | $30.80M | — | -4.1% |
| Total assets | $356.87M | $185.55M | $181.41M | $159.90M | $178.07M | — | +92.3% |
| Total current liabilities | $103.39M | $49.74M | $54.07M | $57.52M | $73.67M | — | +107.9% |
| Current debt | $2.50M | — | $5.63M | $3.75M | $1.88M | $625.00K | — |
| Long-term debt | $36.88M | $59.50M | $47.77M | $50.03M | $56.38M | — | -38.0% |
| Total debt | $53.63M | $74.30M | $68.29M | $69.22M | $74.24M | — | -27.8% |
| Total liabilities | $154.50M | $123.36M | $116.22M | $122.51M | $145.59M | — | +25.2% |
| Retained earnings | -$623.68M | -$734.05M | -$730.12M | -$735.97M | -$751.45M | — | +15.0% |
| Shareholder equity | $162.21M | $49.87M | $55.86M | $43.92M | $22.25M | — | +225.2% |
| Working capital | $192.09M | $74.10M | $64.44M | $52.88M | $53.23M | — | +159.2% |
| Net tangible assets | $135.73M | $22.27M | $27.19M | $14.19M | -$8.55M | — | +509.5% |
| Shares issued | 33.19M | 31.36M | 31.01M | 29.75M | 29.55M | — | +5.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $137.16M | -$5.40M | $8.83M | -$11.65M | -$24.69M | +2,641.4% |
| Depreciation & amortisation | $1.22M | $1.16M | $1.16M | $1.16M | $1.19M | +5.4% |
| Stock-based compensation | $1.76M | $2.46M | $3.20M | $16.79M | $6.29M | -28.6% |
| Change in working capital | $55.79M | -$10.80M | -$4.53M | -$7.48M | -$2.28M | +616.3% |
| Operating cash flow | $203.85M | -$12.54M | -$6.11M | -$27.56M | -$19.56M | +1,725.1% |
| Investing cash flow | $0 | $0 | $2.87M | $6.09M | $1.17M | — |
| Share buybacks | -$14.34M | $0 | $0 | -$115.00K | -$150.00K | — |
| Dividends paid | $0 | -$166.00K | -$166.00K | -$166.00K | -$166.00K | +100.0% |
| Financing cash flow | -$27.39M | $5.71M | $15.07M | $4.52M | $52.14M | -580.0% |
| Free cash flow | $203.85M | -$12.54M | -$6.11M | -$27.56M | -$19.56M | +1,725.1% |
| End cash position | $257.06M | $80.60M | $87.44M | $75.61M | $92.56M | +218.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
2.82
+1.63% from price
SMA 20
2.92
-1.68% from price
SMA 50
3.07
-6.39% from price
SMA 100
2.77
+3.45% from price
SMA 200
3.00
-4.26% from price
EMA 12
2.87
+0.11% from price
EMA 26
2.95
-2.67% from price
EMA 50
2.97
-3.25% from price
RSI (14)
47.0
Neutral
MACD (12,26,9)
-0.08
Hist 0.00
ATR (14)
0.18
6.37% of price
Realised vol 30D
75.3%
Annualised
Bollinger upper
3.38
20, 2σ
Bollinger lower
2.46
20, 2σ
50 / 200 cross
Golden
3.07 vs 3.00
Trend bias
Below 200
-4.26%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.04
More volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
75.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-49.3%
Peak to trough
Max drawdown 5Y
-97.6%
Peak to trough
ATR 14
0.18
6.37% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Fortress Biotech, Inc. Q2 2026 Earnings Call Summary
Moby · 9d ago
Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript
Motley Fool · 9d ago
Fortress Biotech: Q2 Earnings Snapshot
Associated Press · 9d ago
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire · 9d ago
Fortress Biotech Q2 Earnings Call Highlights
MarketBeat · 10d ago
Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
GlobeNewswire · 10d ago
Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
GlobeNewswire · 18d ago
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $130 Million Series B Financing
GlobeNewswire · 27d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.